CB Insights June 17, 2019
Rachel Shope

D2C genomics companies like 23andMe are beginning to expand their product offerings by partnering with companies in other industries.

As a result, synergies between these D2C companies and those of other industries are also starting to take hold. For example, last month 23andMe announced that it’s partnering with travel tech company Airbnb for heritage tourism.

It’s one of the many ways in which these companies are able to extend their product offerings and create more value for their customers.

23andMe, in particular, has had great success here — especially in healthcare —...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Health System / Hospital, Patient / Consumer, Physician, Precision Medicine, Provider, Technology
23andMe: What If …
23andMe CEO Anne Wojcicki considers taking company private
Age of Opportunity: Artificial Intelligence and the Precision Medicine Future
Opinion: Readers respond to OTC antidepressants, personalized medicine, restoring trust in public health, and more
Precision medicine approach combining AI, DNA and drug testing shows gains against relapsed childhood cancers

Share This Article